Enzon sells quarter share in hepatitis drug

Enzon Pharmaceuticals announced Monday it sold a 25 percent share in Schering-Plough Corp.'s Peg-Intron hepatitis...

Want to Read More?

This content is available only to registered users. Log in to read the rest of this article or create a free account.

Login or Register to post a comment.